Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT501 in Rheumatoid Arthritis
NCT07234773Phase 1Recruiting
- Sponsor
- KaliVir Immunotherapeutics
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label trial of KT501 in rheumatoid arthritis (RA), sponsored by KaliVir Immunotherapeutics. Primary endpoints: Incidence of Adverse Events at 12 weeks, Incidence of Cytokine-release Syndrome at 12 weeks and 8 more. Started Mar 2026; status: recruiting.
02
Drugs
KT501
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07234773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234773.